Draft:Perspectum


Perspectum
Company type
Private
IndustryMedical technology
Founded2012
FoundersMichael Brady, Rajarshi Banerjee, Matthew Robson, Stefan Neubauer
HeadquartersOxford, England
Websiteperspectum.com

Perspectum is a British medical technology company based in Oxford, England. The company develops software for the quantitative analysis of magnetic resonance imaging (MRI) scans, with applications in liver disease, metabolic disease, and multi-organ imaging. It originated from research associated with the University of Oxford.[1]

History

Perspectum was founded in 2012 by researchers and clinicians associated with the University of Oxford, including Rajarshi Banerjee, Matthew Robson, Stefan Neubauer, and Michael Brady.[2][3][4][5]

In 2014, Perspectum introduced LiverMultiScan as a research device in Europe and the United States.[6][7] In 2016, LiverMultiScan received clearance from the United States Food and Drug Administration (FDA).[8]

In 2019, Perspectum received an FDA grant to support the evaluation of imaging biomarkers for drug development in non-alcoholic steatohepatitis (NASH).[9] The company secured Series C funding in 2023.[10][11]

In 2024, Perspectum entered into a collaboration with the London Institute for Healthcare Engineering at King's College London on medical imaging research related to metabolic disease and cancer.[12] In January 2026, the company was listed at number 36 in The Sunday Times Tech 100 ranking.[13]

Technology

Perspectum's software analyzes MRI scans to produce quantitative measurements of tissue characteristics, including fat, iron, and fibro-inflammatory changes. Its liver imaging work has included LiverMultiScan, which uses MRI-derived biomarkers such as corrected T1 mapping, proton density fat fraction, and T2* measurements.[14][15] Studies and health-economic analyses have examined LiverMultiScan as an alternative to liver biopsy in some liver-disease pathways, including autoimmune hepatitis and metabolic dysfunction–associated steatotic liver disease.[16][17][18][19]

The company has also developed imaging tools for other clinical and research uses. MRCP+ has been studied for quantitative assessment of the biliary system in conditions such as primary sclerosing cholangitis.[20][21] Hepatica, a liver surgery decision-support tool, received FDA clearance in 2021.[22]

During the COVID-19 pandemic, Perspectum's CoverScan imaging platform was used in research on organ impairment following COVID-19 infection.[23][24][25][26]

References

  1. ^ "Applying AI to MRI". University of Oxford.
  2. ^ "Perspectum". The Sunday Times. 16 January 2026.
  3. ^ "Perspectum Diagnosis". Oxford Mail. 17 April 2014.
  4. ^ "Company focus: Perspectum Diagnostics". PharmaTimes.
  5. ^ "How is AI being used at Oxford?". Ox.ac.uk.
  6. ^ "New study into methods of diagnosing fatty liver disease". Nuffield Department of Population Health, University of Oxford.
  7. ^ Banerjee, Rajarshi; Pavlides, Michael; Tunnicliffe, Elizabeth M.; Piechnik, Stefan K.; Sarania, Nikita; Philips, Rachel; Collier, Jane D.; Booth, Jonathan C.; Schneider, Jurgen E.; Wang, Lai Mun; Delaney, David W.; Fleming, Ken A.; Robson, Matthew D.; Barnes, Eleanor; Neubauer, Stefan (January 2014). "Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease". Journal of Hepatology. 60 (1): 69–77. doi:10.1016/j.jhep.2013.09.002. PMC 3865797. PMID 24036007.
  8. ^ "FDA Clears Perspectum Diagnostics' LiverMultiscan MRI Device". Imaging Technology News. 1 February 2016.
  9. ^ "Perspectum Announces FDA Grant Award for LiverMultiScan to Help NASH Patients". BioSpace. 17 September 2019.
  10. ^ "Significant scale-up investment for three Oxford spinouts". Oxford University. 11 January 2023.
  11. ^ "Perspectum closes on $36M to commercialize Livermultiscan in US". BioWorld.
  12. ^ "Perspectum partners with London Institute for Healthcare Engineering to Advance AI-Powered Medical Imaging Solutions". King's College London.
  13. ^ "Sunday Times 100 Tech 2026: Hardware". The Sunday Times.
  14. ^ "State-of-the-art quantitative MRI for early diagnosis of chronic liver disease". CORDIS. European Commission.
  15. ^ Alexander, Shani. "Early liver disease detection can help prevent heart problems". Bioworld.com.
  16. ^ "MRI-based technologies for assessing non-alcoholic fatty liver disease". NICE. National Institute for Health and Care Excellence. 12 January 2023.
  17. ^ Bajre, Mamta; Moawad, Mina; Shumbayawonda, Elizabeth; Carolan, Jane Elizabeth; Hart, Julie; Culver, Emma; Heneghan, Michael (8 September 2022). "LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England: an economic evaluation". BMJ Open. 12 (9): e058999. doi:10.1136/bmjopen-2021-058999. ISSN 2044-6055. PMC 9462097. PMID 36691214.{{cite journal}}: CS1 maint: article number as page number (link)
  18. ^ Oliver, Gill (17 November 2016). "Liver scan device propels Oxford firm's expansion". Oxford Mail.
  19. ^ "Digital liver scanning technology could halve the number of liver biopsies needed in the NHS". University of Birmingham.
  20. ^ "MRCP+ imaging quantitatively characterizes hepatobiliary diseases". Healio.
  21. ^ Franklin, James; Robinson, Charlotte; Ferreira, Carlos; Shumbayawonda, Elizabeth; Jhaveri, Kartik (6 August 2025). "Exploring the Role of MRCP+ for Enhancing Detection of High-Grade Strictures in Primary Sclerosing Cholangitis". Journal of Clinical Medicine. 14 (15): 5530. doi:10.3390/jcm14155530. PMC 12347560. PMID 40807151.
  22. ^ "FDA clears Perspectum's liver cancer decision tool". AuntMinnie. 27 January 2021.
  23. ^ Yan, Wudan (May 2021). "Can Coverscan Help COVID-19 Survivors?". IEEE Pulse. 12 (3): 18–20. doi:10.1109/MPULS.2021.3078603. ISSN 2154-2317. PMC 8864941. PMID 34156929.
  24. ^ "Dr Louise Thomas works on the first COVID-19 recovery study COVERSCAN". University of Westminster.
  25. ^ "LONG-COVID EXPERTS PERSPECTUM SHARE STARTLING RESEARCH". University of Oxford.
  26. ^ Dennis, Andrea; Wamil, Maryna; Alberts, Jessica; et al. (30 March 2021). "Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study". BMJ Open. 11 (3): e048391. doi:10.1136/bmjopen-2020-048391. PMC 8727683. PMID 33785495.{{cite journal}}: CS1 maint: article number as page number (link)

Category:Medical technology companies of the United Kingdom Category:Companies based in Oxford Category:2012 establishments in the United Kingdom Category:Companies associated with the University of Oxford Category:University spin-offs Category:Technology companies established in 2012

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.